<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163657</url>
  </required_header>
  <id_info>
    <org_study_id>02-01-L</org_study_id>
    <secondary_id>ZEN159</secondary_id>
    <nct_id>NCT00163657</nct_id>
  </id_info>
  <brief_title>Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection</brief_title>
  <official_title>An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among 3 Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For ESLD Caused By Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic - Scottsdale/Phoenix, Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic - Rochester, Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare three treatment regimens in patients who have
      received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C
      infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      End-stage liver disease due to Hepatitis C virus (HCV) infection is the most common reason
      for liver transplantation in the United States. Patients who have HCV will always carry the
      virus in their body. If patients respond to treatment, the virus is no longer active. This
      means that although the virus is still present, it is not currently causing damage to their
      liver.

      Because recurrence of HCV is virtually universal in HCV positive transplant recipients and is
      associated with long term, possibly lethal complications, the search for the most appropriate
      therapies must also include methods to prevent or minimize recurrence or disease progression,
      if the goal of improving long term outcomes for these patients is to be achieved.

      Corticosteroids and high doses of immunosuppressive agents have been associated with
      increased rates of HCV recurrence. Finding a regimen that provides adequate immunosuppression
      to prevent early and late rejection episodes, and minimizes steroid usage as well as high
      doses of other immunosuppressive agents is highly desirable.

      This study is being conducted to determine the most effective immunosuppressive regimen that
      will prevent allograft rejection, minimize adverse events and at the same time, prevent or
      reduce the incidence of HCV recurrence following liver transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom From Acute Rejection or HCV Recurrence or Treatment Failure</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from acute rejection (Banff&gt;grade 2 with RAI score&gt;4) or freedom from HCV recurrence (Batts/Ludwig&gt;Stage 2, or &gt;Grade 3) that requires HCV antiviral therapy or treatment failure (patient death, graft loss, premature withdrawal from study regimen or treatment with more than 1 dose of corticosteroids for presumptive rejection without a biopsy to confirm the rejection; reported values represent the &quot;Number of participants with Freedom From Acute Rejection or HCV Recurrence or Treatment Failure&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom From HCV Recurrence Within First Year That Requires HCV Antiviral Therapy and Freedom From Treatment Failure</measure>
    <time_frame>12 month post transplant</time_frame>
    <description>Participants would have their blood drawn and tested for the HCV virus to determine if they had recurrence</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>End Stage Liver Disease</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>tacrolimus and cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>immunosuppressant treatment regimens the intervention is antirejection treatment with the above labeled drugs tacrolimus and cyclosporine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMF, tacrolimus and cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>immunosuppressant treatment regimensthe intervention is antirejection treatment with the above labeled drugs MMF tacrolimus and cyclosporine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>daclizumub, MMFand tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>immunosuppressant treatment regimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumub</intervention_name>
    <description>anti-rejection drug</description>
    <arm_group_label>tacrolimus and cyclosporine</arm_group_label>
    <arm_group_label>daclizumub, MMFand tacrolimus</arm_group_label>
    <other_name>Zenapax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>anti rejection drug</description>
    <arm_group_label>tacrolimus and cyclosporine</arm_group_label>
    <arm_group_label>MMF, tacrolimus and cyclosporine</arm_group_label>
    <arm_group_label>daclizumub, MMFand tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>anti rejection drug</description>
    <arm_group_label>MMF, tacrolimus and cyclosporine</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
    <description>anti rejection drug</description>
    <arm_group_label>MMF, tacrolimus and cyclosporine</arm_group_label>
    <arm_group_label>daclizumub, MMFand tacrolimus</arm_group_label>
    <other_name>mycophenolate mofetil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has been fully informed and has signed an IRB approved informed consent form
             and is willing and able to follow study procedures for the full 2 years.

          2. Patient is a recipient of a primary whole/split, cadaveric/living donor liver
             transplant for end stage chronic Hepatitis C.

          3. Patient is &gt; age 18.

          4. Female patients of child bearing potential must have a negative urine or serum
             pregnancy test upon hospitalization or within 7 days prior to enrollment and have
             agreed to utilize effective birth control throughout the study as well as for 6 weeks
             following study completion.

        Exclusion Criteria:

          1. Patient has previously received or is receiving an organ transplant other than a
             liver.

          2. Patient has received a liver transplant from a Hepatitis B core antibody or a
             Hepatitis C antibody positive donor.

          3. Patient has received an ABO (blood group anti A, anti B antibodies) incompatible donor
             liver.

          4. Patient has fulminant liver failure with a life expectancy without a liver transplant
             of less than 7 days as defined by UNOS (Adult Patient Status 1, UNOS Policy 3.6.4.1:
             See Appendix C).

          5. Patient has renal dysfunction pre-transplant that, in the opinion of the investigator,
             will prohibit the use of calcineurin inhibitors within 72 hours post transplant.

          6. Patient is intubated, on vasopressors, is ICU bound, or has experienced a significant
             blood loss (greater than 5 units) 72 hours prior to transplant procedure.

          7. Recipient or donor is seropositive for human immunodeficiency virus (HIV) or HbsAg
             positive serology.

          8. Patient is to receive antilymphocyte antibody induction therapy, such as ATGAM
             (lymphocyte immune globulin), OKT3 (muromonab-CD3), Simulect (basiliximab), or
             Thymoglobulin.

          9. Patient has a known hypersensitivity to Prograf (TAC), HCO-60, CellCept (MMF), Zenapax
             or corticosteroids.

         10. Patient is pregnant or lactating.

         11. Patient has participated in a blinded trial or participated in a trial involving a
             non-marketed (investigational) drug within 3 months of enrollment.

         12. Patient has participated in a trial involving a market drug within 30 days. However,
             patients who participated in any interferon or ribavirin trials are permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Klintmalm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Univeristy Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor Regional Transplant Institute - Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>February 23, 2012</results_first_submitted>
  <results_first_submitted_qc>November 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2017</results_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No their is not a plan to make individual Participant data available</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period August 15, 2002-March 29, 2004 Recruitment of liver transplant receipeints from centers transplant program</recruitment_details>
      <pre_assignment_details>Subjects must be receiving a liver transplant for end stage chronic HCV</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm 1</title>
          <description>Immunosuppression TAC (tacrolimus) and CS (cyclosporine)</description>
        </group>
        <group group_id="P2">
          <title>Treatment Arm 2</title>
          <description>Immunosuppression MMF(mofetil mycophenolate), TAC (tacrolimus) and CS (cyclosporine)</description>
        </group>
        <group group_id="P3">
          <title>Treatment Arm 3</title>
          <description>Immunosuppression DAC (daclizumub), MMF (mofetil mycophenolate)and TAC (tacrolimus)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>graft loss</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm 1</title>
          <description>Immunosuppression TAC (tacrolimus) and CS (cyclosporine)</description>
        </group>
        <group group_id="B2">
          <title>Treatment Arm 2</title>
          <description>Immunosuppression MMF(mofetil mycophenolate), TAC (tacrolimus) and CS (cyclosporine)</description>
        </group>
        <group group_id="B3">
          <title>Treatment Arm 3</title>
          <description>Immunosuppression DAC (daclizumub), MMF (mofetil mycophenolate)and TAC (tacrolimus)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="7.2"/>
                    <measurement group_id="B2" value="51.4" spread="7.8"/>
                    <measurement group_id="B3" value="51.5" spread="7.4"/>
                    <measurement group_id="B4" value="51.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reduce HCV recurrent post liver transplant</title>
          <description>Patients receiving a liver transplant for chronic HCV</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Acute Rejection or HCV Recurrence or Treatment Failure</title>
        <description>Freedom from acute rejection (Banff&gt;grade 2 with RAI score&gt;4) or freedom from HCV recurrence (Batts/Ludwig&gt;Stage 2, or &gt;Grade 3) that requires HCV antiviral therapy or treatment failure (patient death, graft loss, premature withdrawal from study regimen or treatment with more than 1 dose of corticosteroids for presumptive rejection without a biopsy to confirm the rejection; reported values represent the &quot;Number of participants with Freedom From Acute Rejection or HCV Recurrence or Treatment Failure&quot;</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm 1</title>
            <description>Immunosuppression TAC (tacrolimus) and CS (cyclosporine)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm 2</title>
            <description>Immunosuppression MMF(mofetil mycophenolate), TAC (tacrolimus) and CS (cyclosporine)</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm 3</title>
            <description>Immunosuppression DAC (daclizumub), MMF (mofetil mycophenolate)and TAC (tacrolimus)</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Acute Rejection or HCV Recurrence or Treatment Failure</title>
          <description>Freedom from acute rejection (Banff&gt;grade 2 with RAI score&gt;4) or freedom from HCV recurrence (Batts/Ludwig&gt;Stage 2, or &gt;Grade 3) that requires HCV antiviral therapy or treatment failure (patient death, graft loss, premature withdrawal from study regimen or treatment with more than 1 dose of corticosteroids for presumptive rejection without a biopsy to confirm the rejection; reported values represent the &quot;Number of participants with Freedom From Acute Rejection or HCV Recurrence or Treatment Failure&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Freedom From HCV Recurrence Within First Year That Requires HCV Antiviral Therapy and Freedom From Treatment Failure</title>
        <description>Participants would have their blood drawn and tested for the HCV virus to determine if they had recurrence</description>
        <time_frame>12 month post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm 1</title>
            <description>Immunosuppression TAC (tacrolimus) and CS (cyclosporine)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm 2</title>
            <description>Immunosuppression MMF(mofetil mycophenolate), TAC (tacrolimus) and CS (cyclosporine)</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm 3</title>
            <description>Immunosuppression DAC (daclizumub), MMF (mofetil mycophenolate)and TAC (tacrolimus)</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From HCV Recurrence Within First Year That Requires HCV Antiviral Therapy and Freedom From Treatment Failure</title>
          <description>Participants would have their blood drawn and tested for the HCV virus to determine if they had recurrence</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>biopsy, labs</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm 1</title>
          <description>Immunosuppression TAC (tacrolimus) and CS (cyclosporine)</description>
        </group>
        <group group_id="E2">
          <title>Treatment Arm 2</title>
          <description>Immunosuppression MMF(mofetil mycophenolate), TAC (tacrolimus) and CS (cyclosporine)</description>
        </group>
        <group group_id="E3">
          <title>Treatment Arm 3</title>
          <description>Immunosuppression DAC (daclizumub), MMF (mofetil mycophenolate)and TAC (tacrolimus)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="45" subjects_affected="40" subjects_at_risk="79"/>
                <counts group_id="E3" events="85" subjects_affected="80" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="45" subjects_affected="40" subjects_at_risk="79"/>
                <counts group_id="E3" events="75" subjects_affected="70" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="45" subjects_affected="40" subjects_at_risk="79"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Goran Klintmalm, MD Director</name_or_title>
      <organization>Baylor University Medical Center</organization>
      <phone>214-820-2050</phone>
      <email>michelle.acker@baylorhealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

